Connectivity, Pharmacology, and Computation: Toward a Mechanistic Understanding of Neural System Dysfunction in Schizophrenia
Alan Anticevic, Michael W. Cole, Grega Repovš, Aleksandar Savič, Naomi R. Driesen, Genevieve Yang, Youngsun T. Cho, John D. Murray, David C. Glahn, Xiao-Jing Wang, John Harrison Krystal
Frontiers in Psychiatry 2013 DOI: 10.3389/fpsyt.2013.00169 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Citations | 78 |
| Key findings | Argues that resting-state neuroimaging reliably detects system-level network disturbances in schizophrenia and bipolar illness but cannot resolve local circuit or single-neuron effects, and proposes that combining ketamine pharmacological challenge in healthy volunteers with biophysically informed computational models can help bridge cellular, systems, and clinical neuroscience approaches to psychiatric disorders. |
Abstract
Neuropsychiatric diseases such as schizophrenia and bipolar illness alter the structure and function of distributed neural networks. Functional neuroimaging tools have evolved sufficiently to reliably detect system-level disturbances in neural networks. This review focuses on recent findings in schizophrenia and bipolar illness using resting-state neuroimaging, an advantageous approach for biomarker development given its ease of data collection and lack of task-based confounds. These benefits notwithstanding, neuroimaging does not yet allow the evaluation of individual neurons within local circuits, where pharmacological treatments ultimately exert their effects. This limitation constitutes an important obstacle in translating findings from animal research to humans and from healthy humans to patient populations. Integrating new neuroscientific tools may help to bridge some of these gaps. We specifically discuss two complementary approaches. The first is pharmacological manipulations in healthy volunteers, which transiently mimic some cardinal features of psychiatric conditions. We specifically focus on recent neuroimaging studies using the NMDA receptor antagonist, ketamine, to probe glutamate synaptic dysfunction associated with schizophrenia. Second, we discuss the combination of human pharmacological imaging with biophysically informed computational models developed to guide the interpretation of functional imaging studies and to inform the development of pathophysiologic hypotheses. To illustrate this approach, we review clinical investigations in addition to recent findings of how computational modeling has guided inferences drawn from our studies involving ketamine administration to healthy subjects. Thus, this review asserts that linking experimental studies in humans with computational models will advance to effort to bridge cellular, systems, and clinical neuroscience approaches to psychiatric disorders.
Citations in the library
Cited by 5
- Effects of serotonin 2A/1A receptor stimulation on social exclusion processing Proceedings of the National Academy of Sciences April 18, 2016
- Role of the 5-HT2AReceptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study Journal of Neuroscience March 19, 2018
- Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia Journal of Psychiatric Research December 24, 2014
- Effects of Subanesthetic Ketamine Administration on Visual and Auditory Event-Related Potentials (ERP) in Humans: A Systematic Review Frontiers in Behavioral Neuroscience April 16, 2018
- Subjective Effects of Ethanol, Morphine, Δ(9)-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity. Brain Connectivity December 2015
Cites 20
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 2003
- Resting-State Functional Connectivity Reflects Structural Connectivity in the Default Mode Network Cerebral Cortex April 9, 2008
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research November 1, 2005
and 15 more in the library